It looks like nothing was found at this location. Maybe try one of the links below or a search?
Recent Posts
- In vivo delivery of CD3-directed CD19-CAR lentivectors leads to the generation of CAR-T and NK-like (CAR-TaNK) cells capable of complete ablation of B cells in the blood, bone marrow, and tissue in NSG-SGM3 CD34+ humanized mice
- EXUMA Biotech Presents Early Clinical and Translational Findings from Solid Tumor Cell Therapy and In Vivo CAR Engineering Research at the AACR Annual Meeting 2023
- Dr. Sid Kerkar speaks with CGT Live about how EXUMA’s TaNK platforms aim to make CAR therapy safer and faster through novel lentivector engineering
- EXUMA Biotech to Present at the 2022 Cancer Immunology and Immunotherapy Conference and to Participate in the 7th Annual CAR-TCR Summit
- In vivo generation of tumor-metabolism-regulated HER2-specific CAR+ cells eradicate established HER2+ gastric carcinomas with the novel subcutaneous route of administration of CD3-directed lentivector-loaded lymphocytes.
Most Used Categories
- Press Releases (20)
- Mentions (11)
- Blog posts (3)
- Presentations (12)
- Posters (11)
Archives
Try looking in the monthly archives. 🙂